Despite availability of current screening measures, such as transvaginal ultrasound, measurement of biomarker CA125 levels [2], or a combination of both modalities, due to the highly heterogeneous nature of ovarian cancer mortality rates remain high. This evidence concerns the gene MUC16 and ovarian carcinoma.